Mammary Cell News Volume 7.22 | Jun 11 2015

CCL2-Induced Chemokine Cascade Promotes Breast Cancer Metastasis by Enhancing Retention of Metastasis-Associated Macrophages
Scientists demonstrated that, through activation of the CC-chemokine ligand 2 (CCL2) receptor CCR2, the recruited metastasis-associated macrophages (MAMs) secrete another chemokine ligand CCL3. Genetic deletion of CCL3 or its receptor CCR1 in macrophages reduces the number of lung metastasis foci, as well as the number of MAMs accumulated in tumor-challenged lung in mice. [J Exp Med] Abstract | Press Release

The Chemokine Receptor CCR6 Facilitates the Onset of Mammary Neoplasia in the MMTV-PyMT Mouse Model via Recruitment of Tumor-Promoting Macrophages
To establish if CCR6 plays a functional role in mammary tumorigenesis, a bigenic MMTV-PyMT CCR6-null mouse was generated and mammary tumor development was assessed. Levels of tumor-infiltrating immune cells within tumor-bearing mammary glands from MMTV-PyMT Ccr6^WT and Ccr6^-/- mice were also analyzed. [Mol Cancer] Full Article

miR-503 Inhibited Cell Proliferation of Human Breast Cancer Cells by Suppressing CCND1 Expression
The authors aimed to elucidate the role of miR-503 in the pathogenesis of breast cancer. Their results suggested that miR-503 expression was markedly downregulated in breast cancer tissues and cells. [Tumor Biol] Abstract

Hispolon Inhibits the Growth of Estrogen Receptor Positive Human Breast Cancer Cells through Modulation of Estrogen Receptor Alpha
The authors investigated the effects of Hispolon on the growth of breast cancer cells. They found that Hispolon decreased expression of estrogen receptor α at both mRNA and the protein levels in MCF7 and T47D human breast cancer cells. [Biochem Biophys Res Commun] Abstract

Myoepithelial and Luminal Breast Cancer Cells Exhibit Different Responses to All-trans Retinoic Acid
Investigators evaluated whether retinoids may differentially regulate cell type-specific processes associated with breast cancer development using the bi-cellular LM38-LP murine mammary adenocarcinoma cell line as a model. [Cell Oncol] Abstract

Kruppel-Like Factor 4 Signals through MicroRNA-206 to Promote Tumor Initiation and Cell Survival
Researchers found that both expand to Kruppel-like factor 4 and a downstream effector, microRNA-206, are selectively enriched in the mammary cancer stem-like cell (MaCSC) fractions of cultured human triple-negative breast cancer cell lines, as well as in the aldehyde dehydrogenase-high MaCSC sub-population of cells derived from xenografted human mammary carcinomas. [Oncogenesis] Full Article

CLINICAL RESEARCH

Randomized Phase III Trial of Paclitaxel Once per Week Compared with Nanoparticle Albumin-Bound Nab-Paclitaxel Once per Week or Ixabepilone with Bevacizumab as First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)
Investigators compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as first-line therapy for patients with advanced breast cancer to evaluate progression-free survival for nab-paclitaxel or ixabepilone versus paclitaxel. [J Clin Oncol] Abstract

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
Researchers conducted a randomized Phase III study to determine whether patients with early breast cancer would benefit from the addition of capecitabine to a standard regimen of doxorubicin plus cyclophosphamide followed by docetaxel. [Clin Cancer Res] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

The University Hospital UZ Leuven and Philips Collaborate to Improve Cancer Diagnostics through Digital Pathology
Royal Philips and UZ Leuven, announced a collaboration to digitize and optimize cancer research through digital pathology. The largest university hospital in Belgium will be the first hospital in the country to deploy the Philips IntelliSite Pathology Solution with the aim, through research, to enable faster and more confident diagnosis of cancer and better treatment for patients. [Royal Philips] Press Release

STEMCELL Technologies Named Company of the Year by BIOTECanada
STEMCELL Technologies Inc. will be presented with the Biotech Company of the Year award by BIOTECanada at this year’s BIO International Convention in Philadelphia. [BIOTECanada] Press Release

From our sponsor:
Webinar: Brent Reynolds on the identification and characterization of neural stem cells. Watch now.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Academic Breast Pathologist (Brigham & Women’s Hospital)

Assistant/Associate/Full Professor – Oncology (Shanghai Jiao Tong University School of Medicine)

Postdoctoral Research Assistant – Role of BRCA1 in the Repair of DNA Damage (University of Dundee)

Postdoctoral Position – Malignant Breast Cancer Cells in the Bone Marrow Microenvironment (Duke University)

Postdoctoral Position – Fatty Acid Metabolism Inhibition on Chemoresistant TNBC Models (University of Girona)

Postdoctoral Fellow – Regulation of Growth and Survival of Breast Cancer Cells (Icahn School of Medicine at Mount Sinai)

Postdoctoral Technician – Prostate/Breast Cancer (Baylor College of Medicine)

Postdoctoral Research Fellow/Instructor – Prostate/Breast Cancer (Baylor College of Medicine)

Postdoctoral Positions – Molecular Cancer Biology (University of Pennsylvania)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.